Table 2.

Hazard ratios (HR) and 95% confidence intervals (CI) for characteristics associated with recurrence for incident melanoma, stages I‐III, Kaiser Permanente Colorado, 2000‐2015

	Observations	Unadjusted HR	95% CI	Adjusteda HR	95% CI	P‐value	Adjustedb HR	95% CI	P‐value
Stage I	1486	Ref		Ref			Ref
Stage II	272	6.37	4.43‐9.18	5.54	3.83‐8.03	<0.0001	5.27	3.63‐7.67	<0.0001
Stage III	94	19.54	13.24‐28.82	18.58	12.51‐27.61	<0.0001	16.23	10.45‐25.19	<0.0001
Female	788	Ref		Ref			Ref
Male	1064	2.20	1.55‐3.12	1.72	1.21‐2.45	0.003	1.70	1.19‐2.43	0.003
Age in decades		1.29	1.15‐1.43	1.18	1.04‐1.33	0.009	1.20	1.06‐1.37	0.005
White	1816	Ref		Ref			Ref
Non‐White	36	1.22	0.45‐3.29	1.81	0.66‐4.97	0.251	1.86	0.68‐5.12	0.228
Socioeconomic status		0.44	0.20‐0.96	0.74	0.33‐1.67	0.466	0.75	0.33‐1.69	0.486
Comorbid conditions: 0	1084	Ref		Ref			Ref
Comorbid conditions: 1‐2	511	1.48	1.04‐2.10	1.10	0.77‐1.58	0.602	1.14	0.79‐1.64	0.494
Comorbid conditions: 3+	257	2.04	1.35‐3.08	1.12	0.72‐1.76	0.614	1.10	0.71‐1.73	0.665
No radiation	1845	Ref					Ref
Radiation	7	10.69	3.96‐28.89				3.03	1.10‐8.36	0.0328
No chemotherapy	1849	Ref					Ref
Chemotherapy	3	3.85	0.54‐27.62				0.80	0.11‐6.13	0.833
No biologic response modulators	1803	Ref					Ref
Biologic response modulators	49	6.60	4.13‐10.54				1.51	0.86‐2.68	0.155

^aAdjusted for stage, gender, age as a continuous variable, race/ethnicity, socioeconomic status as measured by percent of college educated households in census tract of residence, and comorbidity index

^bThis model adds dichotomous variables for the type of treatments received in addition to the covariates listed in the prior model. Surgery was not included as all but one case received surgery as part of treatment